Cancer Center Support Grant P30

项目总结/摘要 加州大学戴维斯分校综合癌症中心（UCDCCC），与劳伦斯利弗莫尔国家联盟 实验室（LLNL），是一个矩阵组织的庇护下，加州大学戴维斯分校卫生系统和大学 加州，戴维斯。204名成员被组织成六个项目，由八个共享项目支持。 资源，并由高级领导层领导，以利用跨学科，翻译和变革 研究以解决以下问题：随着人口迅速老龄化，4000万美国人超过年龄 65人今天还活着，今年将有39万人死于癌症。在15年里，大约有7400万人 这个年龄段的美国人将活着，癌症死亡率将达到约730，000/年。目前的方法， 已经开发的新的癌症疗法已经遇到了令人失望的失败率;因此，改进的 需要翻译方法。联合收割机结合物理科学、生物医学和生物医学的综合项目也是如此。 技术和功能成像，以开发新的治疗和递送方式以及用于 功能评估和增强的检测，以确定，在一个无毒的方式，如果治疗将工作。 解决这些问题的两个主要重点是： 1)减少癌症负担的差距 2)通过我们的患者衍生的分子靶向治疗来应对晚期癌症 异种移植计划（PDX）和犬患者，以真正开发个性化医疗。 每一个都使用多学科的方法，结合了来自各个项目的专业知识（分子生物学）。 肿瘤学，比较肿瘤学，癌症治疗学，人口科学和健康差异，前列腺 尿路上皮癌和生物医学技术），利用加州大学戴维斯分校的专业知识（例如，医学院， 兽医学院、生物科学学院、生物医学技术系），以及 与外部合作伙伴（杰克逊实验室、劳伦斯利弗莫尔国家实验室、基金会 医学）。七个创新小组加强协作互动和建议，重点是 将基础和技术成果转化为赠款和资助者发起的试验（IIT）。除此之外， UCDCCC强大的临床试验计划使这些发现能够转化为患者的利益。的 投资组合包括NCI奖项，用于资助I期，II期和III期试验，COG和NCI比较肿瘤学试验 联盟试验，以及强大的IIT组合。这些都是由一个骨干临床科学家（11 在过去的资助期内招募），他们作为翻译和临床的接口， research.集水区（萨克拉门托县周围的13个县）通过以下方式受益： 活动，全市早期临床试验计划和UCDCCC癌症护理网络，通过 将综合癌症中心的资源和专业知识带到贫困和农村地区， 同时让患者留在自己的社区。最后，在这个不断变化的癌症护理世界中， 交付模式，加上越来越多的患者寻求帮助， 我们正在建立一个强大的癌症支持/心理肿瘤学计划。

PROJECT SUMMARY/ABSTRACT The UC Davis Comprehensive Cancer Center (UCDCCC), a consortium with Lawrence Livermore National Laboratories (LLNL), is a matrix organization under the aegis of the UC Davis Health System and University of California, Davis. Two hundred and four members are organized into six programs, supported by eight shared resources, and led by Senior Leadership in order to use transdisciplinary, translational, and transformative research to address the following problems: With a rapidly aging population, 40 million Americans over the age of 65 are alive today and 390,000 will die from cancer this year. In 15 years, approximately, 74 million Americans of this age will be alive and cancer mortality will be ~730,000/year. The present methods by which new cancer therapies have been developed have met with a disappointing failure rate; therefore, improved translational methods are needed. So too are integrated programs that combine physical sciences, biomedical technology, and functional imaging to develop new therapies and delivery modalities as well as methods for functional evaluation and enhanced detection to determine, in a non-toxic fashion, if therapies will work. Two main foci are used to address these problems: 1) Reducing disparities in the cancer burden 2) Tackling advanced cancer by adapting molecularly targeted therapy through our patient derived xenograft program (PDX) and canine patients to truly develop personalized medicine. Each of these uses a multi-disciplinary approach, combining expertise from across programs (Molecular Oncology, Comparative Oncology, Cancer Therapeutics, Population Sciences and Health Disparities, Prostate Urothelial Cancer, and Biomedical Technology), leveraging the UC Davis expertise (e.g., School of Medicine, School of Veterinary Medicine, College of Biological Sciences, Department of Biomedical Technology), and with external partners (the Jackson Laboratory, Lawrence Livermore National Laboratory, Foundation Medicine). Seven Innovation Groups enhance collaborative interactions and proposals with focus on translating basic and technological findings into grants and investigator-initiated trials (IITs). Beyond that, the UCDCCC’s robust clinical trials program enables these discoveries to be translated into patient benefits. The portfolio consist of NCI awards to fund Phase I, II, and III trials, COG and NCI Comparative Oncology Trials Consortium trials, and a strong portfolio of IITs. These are implemented by a cadre of clinical scientists (11 of whom were recruited in the past funding period) who function as the interface of translational and clinical research. The catchment area (13 counties surrounding Sacramento county) is benefited through, among other activities, a city-wide early phase clinical trials program and the UCDCCC Cancer Care Network, through which the resources and expertise of a comprehensive cancer center are brought to disadvantaged and rural areas while keeping patients in their home communities. Finally, in this world of ever-changing cancer care delivery models, combined with an increasing numbers of patients seeking help and increasing complexities of treatments available, we are building a robust cancer supportive/psycho oncology program.